In the plck-GAPDH mice, which demonstrated strong activation of the non-canonical NF-κB pathway, treatment with a novel small-molecule inhibitor of NIK resulted in much lower tumor development and in a higher survival rate (patent PCT/EP2017/067306). This evidence concerns the gene GAPDH and neoplasm.